Abivax SA (NASDAQ:ABVX) is a biopharmaceutical company focused on developing therapies for inflammatory diseases. The company is gaining attention due to its promising drug, obefazimod, which targets moderate-to-severe ulcerative colitis. Piper Sandler recently set a price target of $142 for ABVX, suggesting a potential increase of 27.95% from its current price of $110.98.
The "Strong Buy" rating for ABVX is largely driven by the positive phase 3 ABTECT induction data for obefazimod. This drug's oral dosing and favorable safety profile, along with its novel miR-124 mechanism, make it a strong contender in the ulcerative colitis therapy market. Abivax is also looking to expand obefazimod's use into Crohn's disease treatment.
Abivax anticipates significant developments in 2026, including the release of 44-week maintenance data from the ABTECT trials in the second quarter. If results remain positive, the company plans to file for New Drug Application (NDA) and Marketing Authorization Application (MAA) in the second half of 2026. These milestones could further boost ABVX's market position.
Currently, ABVX's stock price is $110.98, reflecting a decrease of 5.88% or $6.93. The stock has fluctuated between $108.55 and $115.61 today. Over the past year, it has seen a high of $138.49 and a low of $4.77. With a market capitalization of approximately $8.38 billion, ABVX remains a significant player in the biopharmaceutical industry.
